New developments in diabetes technology: Patch pumps and glucose sensor manufacturers unveil upcoming products at the ADA (American Diabetes Association) conference.
In the ever-evolving world of diabetes management, several companies are making strides in developing new insulin delivery systems. One of the leading names, Medtronic, is currently in the spotlight with its upcoming insulin patch pump.
Medtronic's New Patch Pump
Medtronic's next continuous glucose monitor, the G8, is currently undergoing human feasibility trials. Simultaneously, the company is working on a new modular patch pump, expected to be released around 2025-2026. This device is anticipated to hold 300 units of insulin, about 50% more than their current pumps, and use a 7-day infusion set, which is longer-lasting than the typical 3-day sets. The new pump might also include multiple pieces, similar to the Siggy pump concept, and be customizable with different colors.
The MiniMed 780G system, Medtronic's current system, is already available and undergoing label expansions, including for Type 2 diabetes and young children. It is tubed rather than tubeless and will continue evolving. However, the upcoming patch pump aims to improve on these aspects by being modular, potentially tubeless, and offering a longer 7-day infusion set lifespan.
Competitors' Developments
While specific release dates and detailed features for new patch pumps from Tandem Diabetes Care, Beta Bionics, and Insulet are not yet available, these companies are also focusing on tubeless patch pump designs integrating automated insulin delivery and continuous glucose monitoring (CGM) systems. Since Medtronic is releasing an extended infusion set modular pump in the near term, it may be inferred that competitors like Tandem, Beta Bionics, and Insulet may have developments targeted in a similar timeframe (2025-2026).
Other Notable Developments
Abbott is also planning to launch a device next year that can detect both glucose and ketone levels. Senseonics is working on a fully implantable, self-powered glucose sensor called Gemini, with a planned study later this year and a commercial launch in Q4 2026. Dexcom is developing the Dexcom G8 sensor, which will last for 15 days, have a smaller form factor than the current G7, and support multi-analyte capabilities.
In conclusion, Medtronic's new insulin patch pump with modular design, longer infusion sets, and increased insulin capacity is anticipated around 2025-2026, with details still emerging. For Tandem, Beta Bionics, and Insulet, no specific release dates or detailed features are available as of now. All these companies focus on integrating patch pump insulin delivery with CGM for automated, user-friendly diabetes management.
As these devices approach release, updates will be monitored to keep readers informed about the latest advancements in diabetes management technology.
- In the realm of health and wellness, Medtronic's new insulin patch pump is poised to revolutionize diabetes management, as it undergoes human feasibility trials.
- The G8, Medtronic's next continuous glucose monitor, is also in development, with a modular patch pump expected to follow around 2025-2026.
- This upcoming device from Medtronic could potentially hold 300 units of insulin, an increase of 50% over current pumps, and incorporate a longer-lasting 7-day infusion set.
- The new pump may also feature a modular design, similar to the Siggy pump concept, and offer customizable colors for user preferences.
- Medtronic's MiniMed 780G system, already available, is undergoing label expansions for Type 2 diabetes and young children, and is predicted to evolve further.
- In the medtech industry, competitors such as Tandem Diabetes Care, Beta Bionics, and Insulet are also focusing on tubeless patch pump designs with automated insulin delivery and CGM systems.
- Science and technology advancements in this sector are not limited to insulin delivery devices, as Abbott plans to launch a device next year detecting both glucose and ketone levels.
- Senseonics is working on a fully implantable, self-powered glucose sensor called Gemini, with a planned study and commercial launch scheduled for Q4 2026.
- Dexcom is developing the Dexcom G8 sensor, promising a 15-day lifespan, smaller form factor, and multi-analyte capabilities, adding to the list of notable advancements in diabetes management technology.
%20conference.){kind=link}